All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-11-10T13:05:59.000Z

Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?

Nov 10, 2023
Share:
Learning objective: After reading this article, learners will be able to cite new clinical developments in ALL.

During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkin, Baylor College of Medicine, Houston, US. We asked, Is chimeric antigen receptor (CAR) T-cell therapy a safe and effective treatment option for relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma.

 

Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?

Firstly, Mamonkin discusses recent progress made in the development and evaluation of CAR T-cell therapies in T-ALL and lymphoma. He highlights several strategies that have yielded encouraging results, including autologous CD7-directed CAR T-cell therapies utilizing various methods, such as gene editing to prevent the risk of fratricide in China, CRISPR-based editing of anti-CD7 CAR T cells in the UK, and unedited CD7-directed CAR T cells in the US.

He goes on to mention challenges in the field, including preventing the risk of fratricide, reducing ablation of circulating endogenous CAR T cells, T-cell aplasia, and antigen escape. One alternative approach currently being investigated to overcome antigen escape is the use of different antigen targets, such as CD5-directed CAR T cells. Both CD7 and CD5-directed CAR T-cell therapies are paving the way in the treatment of R/R T-ALL.

 

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox